CAJ | 학술논문

目的：：研究肝细胞癌合并门静脉高压的肝切除术治疗效果及安全性。方法：回顾分析168例肝细胞癌患者的临床资料，按是否合并门静脉高压分为合并组(51例)与未合并组(117例)，比较两组术后1、3、5年生存率。结果：合并组术后3年、5年生存率(45．10%、31.37%)均低于未合并组(66．67%、47．86%)(P=6．8915、P=3．9440)。合并组肝段切除≥3段患者术后1、3、5年生存率(67．57%、37．84%、29．73%)均低于未合并组(84．15%、67．07%、51.22%)(P=4．2228、P=8．9446、P=4．7666)。结论：肝切除术治疗肝细胞癌合并门静脉高压，需严格选择患者，控制肝段切除范围。
목적：：연구간세포암합병문정맥고압적간절제술치료효과급안전성。방법：회고분석168례간세포암환자적림상자료，안시부합병문정맥고압분위합병조(51례)여미합병조(117례)，비교량조술후1、3、5년생존솔。결과：합병조술후3년、5년생존솔(45．10%、31.37%)균저우미합병조(66．67%、47．86%)(P=6．8915、P=3．9440)。합병조간단절제≥3단환자술후1、3、5년생존솔(67．57%、37．84%、29．73%)균저우미합병조(84．15%、67．07%、51.22%)(P=4．2228、P=8．9446、P=4．7666)。결론：간절제술치료간세포암합병문정맥고압，수엄격선택환자，공제간단절제범위。
Objective:To study the clinical efficacy and safety of liver resection for patients with portal hypertension and hepa-tocellular carcinoma. Methods:Retrospectively analyzed the clinical data of 168 patients with hepatocellular carcinoma,51 cases of pa-tients combined with portal hypertension were divided into combined group,and 117 cases with no combination were in non-combined group. The survival rates were compared 1,3,5 years after the surgery respectively. Results:The survival rates of combined group (3-year 45. 10%,5-year 31. 37%) were lower than those of non-combined group (3-year 66. 67%,5-year 47. 86%) (P=6. 891 5,P=3. 944 0). Patients with liver section≥3 segments in combined group had lower survival rates than non-combined group 1,3,5 years after the surgery respectively (67. 57%,37. 84%,29. 73% and 84. 15%,67. 07%,51. 22%) ( P=4. 222 8,P=8. 944 6,P=4. 766 6). Conclusion:Liver resection for hepatocellular carcinoma with portal hypertension should strictly select patients and control the he-patic resection range.